Related Experiment Video
Updated: May 22, 2026

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
Published on: March 13, 2018
The NeVa stent-retriever - a single-centre real-world experience
Pervinder Bhogal1, Marco Mancuso-Marcello1, Rory Fairhead1
1Department of Interventional Neuroradiology, The Royal London Hospital, Whitechapel Road, London, UK.
The NeVa stent retriever achieved a high first-pass effect (FPE) in 57% of acute ischemic stroke patients. This mechanical thrombectomy approach demonstrated excellent recanalization rates, supporting its use in large vessel occlusion stroke treatment.
Area of Science:
- Neurology
- Interventional Neuroradiology
- Vascular Medicine
Background:
- Mechanical thrombectomy (MT) using stent retrievers is a key treatment for acute ischemic stroke (AIS) from large vessel occlusion (LVO).
- First-pass effect (FPE) is a critical predictor of successful outcomes in LVO AIS patients undergoing MT.
Purpose of the Study:
- To evaluate the real-world efficacy of the NeVa stent retriever in achieving FPE and successful recanalization in LVO AIS patients.
- To analyze factors associated with FPE and functional outcomes in a prospectively maintained registry.
Main Methods:
- Independent central reader review of 89 consecutive LVO AIS patients treated with the NeVa stent retriever.
- Analysis of procedural parameters including device length, use of Balloon Guide Catheter (BGC), and distal aspiration.
- Assessment of first-pass effect (eTICI ≥2c) and final recanalization (eTICI ≥2c).
Main Results:
- FPE (eTICI ≥2c) was achieved in 57% of patients; modified FPE (eTICI ≥2b) in 65.1%.
- Final successful recanalization (eTICI ≥2c) was achieved in 87% of cases.
- Good functional outcome (mRS ≤2) was observed in 40% of patients.
Conclusions:
- The NeVa stent-retriever demonstrates a high rate of FPE and final recanalization in a real-world setting.
- The use of longer NeVa devices, BGC, and proximal aspiration may optimize FPE.
- These findings support the effectiveness of the NeVa stent retriever for LVO AIS treatment.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

